José A. López-Martín
PharmaMar (Spain)(ES)Precision Research (United States)(US)
Publications by Year
Research Areas
Sarcoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, CAR-T cell therapy research
Most-Cited Works
- → Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study(2019)2,871 cited
- → Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study(2020)2,424 cited
- → Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial(2016)1,248 cited
- → Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies(2019)430 cited
- → Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results(2019)242 cited